Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 4Skin Neoplasms 3Skin Diseases 2Neoplasm Metastasis 2Neoplasms 1Low-grade Serous Ovarian Cancer 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Dacarbazine 4pembrolizumab 3binimetinib 3Nivolumab 3encorafenib 2cemiplimab 2Sirolimus 2Ipilimumab 2vitespin 1trametinib 1tilsotolimod 1spartalizumab 1oblimersen 1linrodostat 1lifileucel 1gp100 Melanoma Antigen 1dabrafenib 1bempegaldesleukin 1aldesleukin 1Vinblastine 1Vemurafenib 1Tretinoin 1Tacrolimus 1Standard of Care 1Sodium Chloride 1Radiotherapy 1Radiation 1Interleukin-2 1Interferon-alpha 1Interferon alpha-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Skin Neoplasms × binimetinib × Clear all
NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Pfizer

Phase 3 Active not recruiting
257 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT01909453 2026-02-27

COLUMBUS

Pfizer

Phase 3 Completed
921 enrolled 48 charts 1 FDA
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Pfizer

Phase 3 Completed
402 enrolled 21 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡